Union Health Ministry Expands QR Code-Based Drug Traceability Framework to Vaccines, Antimicrobials and Anti-Cancer Medicines

The Ministry of Health and Family Welfare notified amendments to the Drugs Rules, 1945, bringing vaccines, antimicrobials, narcotic and psychotropic drugs, a...

What Happened

The Ministry of Health and Family Welfare notified amendments to the Drugs Rules, 1945, bringing vaccines, antimicrobials, narcotic and psychotropic drugs, and all anti-cancer medicines under the QR Code-based track and trace framework.
The expanded framework requires manufacturers to print or affix a Bar Code or Quick Response (QR) Code on primary packaging labels (or secondary labels if space is insufficient).
The QR Code must store a unique product identification code, generic and brand names, manufacturer name and address, batch number, manufacturing and expiry dates, manufacturing licence number, and excipient details.
Implementation timelines are staggered: vaccines, anti-cancer medicines, and narcotic/psychotropic drugs from July 1, 2027; antimicrobials from July 1, 2028.
The QR code-based identification requirement was previously applicable only to the top 300 pharmaceutical brands; this amendment significantly broadens coverage.

Static Topic Bridges

Schedule H2 and the Drugs Rules, 1945

Schedule H2 is a category under the Drugs Rules, 1945 (framed under the Drugs and Cosmetics Act, 1940) that covers high-risk drugs requiring stringent regulation. It was introduced to impose additional control measures — including mandatory QR codes, restricted sale only on prescription, and maintenance of patient-wise records by pharmacists — over drugs with significant abuse potential or public health risk. The Drugs and Cosmetics Act, 1940 is the primary legislation governing drug manufacture, distribution, and sale in India, and the Drugs Rules, 1945 is its subordinate legislation providing operational guidelines.

Schedule H: Prescription-only drugs (cannot be sold without a doctor's prescription).
Schedule H1: Higher-risk subset — includes anti-tuberculosis drugs, some anti-infectives, and second-line antibiotics. Requires pharmacist to maintain records of sale for two years.
Schedule H2: Highest-risk subset — previously included select drugs prone to counterfeiting and misuse; now expanded to vaccines, antimicrobials, and anti-cancer drugs.
Implementing regulator: Central Drugs Standard Control Organisation (CDSCO), under the Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare.
CDSCO is India's national regulatory authority for pharmaceuticals and medical devices, analogous to the US FDA.

Connection to this news: The amendment expands Schedule H2's scope, making QR code-based traceability mandatory for a far larger category of medicines, strengthening CDSCO's regulatory oversight over the pharmaceutical supply chain.

Track and Trace System for Pharmaceuticals

The Track and Trace System is India's serialisation-based mechanism to assign a unique identity to each unit of medicine, enabling it to be tracked from manufacturer to patient. The system aims to eliminate counterfeit and spurious medicines by allowing any stakeholder — regulator, pharmacist, or patient — to verify a drug's authenticity through a digital scan. Globally, similar frameworks exist under the EU Falsified Medicines Directive and the US Drug Supply Chain Security Act (DSCSA).

Serialisation assigns a unique product identification number to every batch and unit.
Information encoded in the QR code is accessible via software applications for real-time authentication.
The system enables end-to-end supply chain visibility: manufacturer → distributor → stockist → retailer → patient.
Counterfeit and substandard medicines are a global public health problem; the WHO estimates up to 10% of medicines in low- and middle-income countries are substandard or falsified.

Connection to this news: Extending QR codes to vaccines and antimicrobials directly addresses two critical public health imperatives: maintaining cold-chain integrity and verification for vaccines, and combating Anti-Microbial Resistance (AMR) by curbing counterfeit antibiotics.

Anti-Microbial Resistance (AMR)

AMR occurs when bacteria, viruses, fungi, and parasites evolve to resist the drugs designed to kill them. Substandard or counterfeit antimicrobials — those with insufficient active ingredients — expose pathogens to sub-lethal doses, accelerating resistance development. India is one of the largest consumers of antibiotics globally and carries a disproportionate AMR burden. The National Action Plan on AMR (2017–2021) and its successor frameworks recognise drug quality surveillance as a key pillar of AMR containment.

WHO has listed AMR as one of the top 10 global public health threats.
India's high over-the-counter antibiotic sales make traceability-based controls particularly important.
The 2028 implementation deadline for antimicrobials gives manufacturers time to build serialisation infrastructure.

Connection to this news: The mandatory QR code requirement for antimicrobials is explicitly framed in the amendment as a measure to support the national fight against AMR by enabling identification and monitoring of counterfeit and substandard antimicrobial products.

Key Facts & Data

Legal basis: Drugs and Cosmetics Act, 1940; Drugs Rules, 1945 (Schedule H2 amendment notified June 2026).
Regulator: Central Drugs Standard Control Organisation (CDSCO).
Earlier scope of QR code mandate: Top 300 pharmaceutical brands only.
New categories added: All vaccines, all antimicrobials, all anti-cancer drugs, narcotic and psychotropic drugs (under NDPS Act, 1985).
Effective date for vaccines/anti-cancer/narcotics: July 1, 2027.
Effective date for antimicrobials: July 1, 2028.
QR code must contain: unique product ID, generic name, brand name, manufacturer name and address, batch number, manufacturing date, expiry date, manufacturing licence number, excipient details.
WHO estimate: Up to 10% of medicines in low- and middle-income countries are substandard or falsified.